Amgen Inc. sued Novartis AG’s Sandoz in New Jersey federal court Monday, accusing Sandoz’s proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.
https://www.pharmalive.com/wp-content/uploads/2020/09/Amgen-drug-shrinks-tumors-in-lung-cancer-patients-with-KRAS-gene-mutation-–-study-Reuters-9-19-20.jpeg133200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-05-02 18:35:592023-05-03 09:44:25Amgen sues Novartis to block generic osteoporosis, bone cancer drugs
